Search results
Results From The WOW.Com Content Network
In the US, the FDA has approved two oral cannabinoids for use as medicine in 1985: [136] dronabinol (pure delta-9-THC; brand name Marinol) and nabilone (a synthetic neocannabinoid; brand name Cesamet). [6] In the US, they are both listed as Schedule II, indicating high potential for side effects and addiction. [53] [137]
Dronabinol (INN Tooltip International Nonproprietary Name), sold under the brand names Marinol and Syndros, is the generic name for the molecule of (−)-trans-Δ 9-tetrahydrocannabinol (THC) in the pharmaceutical context.
Although cannabis is legalized for medical uses in more than half of the states of the United States, no products have been approved for federal commerce by the Food and Drug Administration, a status that limits cultivation, manufacture, distribution, clinical research, and therapeutic applications.
An ancient Akkadian name originating before the 5th century (400 CE). [47] ้บป (Má) Má, a Chinese name for hemp, predates written history and has been used to describe medical marijuana since at least 2700 BCE. It is the earliest recorded name. [48] [49] Hemp is recorded in the Book of Documents. [5] [26] Ma-kaña Bantu. [50] Maconha
Marijuana has a lower potential for abuse than other drugs that are subjected to the same restrictions, with some scientific support for its use as a medical treatment, researchers from the US ...
Nabiximols (brand name Sativex), an oromucosal spray made of a complex botanical mixture containing cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and additional cannabinoid and non-cannabinoid constituents from cannabis sativa plants, was approved by Health Canada in 2005, to treat central neuropathic pain in multiple sclerosis, and in ...
Dronabinol (brand names Marinol and Syndros) is a delta-9-THC containing drug for treating HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting. [58] The CBD drug Epidiolex has been approved by the Food and Drug Administration for treatment of two rare and severe forms of epilepsy, [59] Dravet and Lennox-Gastaut syndromes. [60]
German medical cannabis flower revenue jumped 50% following regulatory changes that expanded market access and patient reach. Tilray's brand-first strategy sets it apart from many cannabis peers.